ADC TherapeuticsADCT
Market Cap: $261M
About: ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
Employees: 274
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
543% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 7
468% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $201K
103% more funds holding
Funds holding: 37 [Q1] → 75 (+38) [Q2]
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
8.53% more ownership
Funds ownership: 45.32% [Q1] → 53.85% (+8.53%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
3% less capital invested
Capital invested by funds: $168M [Q1] → $164M (-$4.25M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Robert Burns 40% 1-year accuracy 57 / 144 met price target | 196%upside $8 | Buy Reiterated | 8 Aug 2024 |
RBC Capital Gregory Renza 45% 1-year accuracy 32 / 71 met price target | 196%upside $8 | Outperform Reiterated | 7 Aug 2024 |
Financial journalist opinion
Based on 3 articles about ADCT published over the past 30 days